Second phase 2/3 placebo-controlled trial of PBI-4050 in Idiopathic Pulmonary Fibrosis patients who have failed to tolerate nintedanib or pirfenidone.
Phase of Trial: Phase II/III
Latest Information Update: 10 May 2017
At a glance
- Drugs PBI 4050 (Primary)
- Indications Pulmonary fibrosis
- Focus Therapeutic Use
- 10 May 2017 According to a ProMetic Life Sciences media release, the company scheduled to initiate this trial in second quarter of 2017.
- 20 Apr 2017 New trial record